Welcome, Guest
Username: Password: Remember me
Adult Stem Cell News and Developments other than Cytori
  • Page:
  • 1

TOPIC: Tigenix Licenses from Mesoblat

Tigenix Licenses from Mesoblat 17 Dec 2017 17:39 #10813

  • rongside
  • rongside's Avatar Topic Author
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 388
  • Thank you received: 196
Being first in getting approval is great but not the chief determinant of financial success. CYTX has an IIS study being undertaken for Fistula in Ano from Crohn's disease. The results should not be too far off. With Tigenix approval the wall is broken for stem cell therapy. I provides a significant opportunity for CYTX o also benefit. ADRC could pose a significant challenge for Tigenix's product. I personaly believe that the autologous treament ma be better than the allogeneic. We have considerable safety and efficacy data in this indication. The French trial data could provide a considerable inducement for someone to partner with CYTX


The questions that will be crucial are (1) the ability to defend the treament paradigm with robust patent protection, (2) the relative cost of he lipo vis a vis cost of allogeneic manufacture, (3) the relative effectiveness of auto vs allo, and my personal favorite (4) how do you jusif differential pricing for hesame produc in differen indications.*

All of the above is predictaed on management growing some balls and being prepared to make a deal wih BB/BP and to cut themseves free from the apron strings/noose of the invesment bank financiers which are in cahoots with short selling arbitrageurs. A BIG IF.

Personally for the benefit of society I would like to see low pricing across the board.
The following user(s) said Thank You: rodney.strongg, b767cpt

Please Log in or Create an account to join the conversation.

Tigenix Licenses from Mesoblat 18 Dec 2017 09:59 #10814

  • b767cpt
  • b767cpt's Avatar
  • Offline
  • Gold Boarder
  • Gold Boarder
  • Posts: 303
  • Thank you received: 4
Interesting that the study completion date is next month, perhaps this will propel the pps with good study results.

Please Log in or Create an account to join the conversation.

Tigenix Licenses from Mesoblat 18 Dec 2017 10:46 #10815

  • fas
  • fas's Avatar
  • Offline
  • Moderator
  • Moderator
  • May the fat be with you
  • Posts: 3358
  • Thank you received: 1116
Both John and I know that the Marseille IIS is not the only study on fistula after Crohn´s. Cytori already received device claims on the indication in 2010 in the UK- of course as a result of positive data, which most likely were owned by Olympus. Nonetheless, this tragedy of missed opportunities, resulting of managerial incompetence, was followed by more and similar studies and data definitely better than what I read in the Tigenix results (where the primary endpoint was against standard of care) . Anyway- it is what it is at present.

Just wanted also to note that the PPS jump on Friday had little to do with the MSB license deal but the positive opinion of the CHMP/CAT in Europe- see below-

Osaka, Japan, December 15, 2017 and Leuven, Belgium, December 15, 2017, 13:10h CET – Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) and TiGenix NV (Euronext Brussels and NASDAQ: TIG) (“TiGenix”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), in conjunction with the Committee for Advanced Therapies (CAT), has adopted a positive opinion recommending a marketing authorization (MA) for investigational compound Cx601 (darvadstrocel). Cx601 is expected to be indicated for the treatment of complex perianal fistulas in adult patients with non-active/mildly active luminal Crohn’s disease, when fistulas have shown an inadequate response to at least one conventional or biologic therapy.2 This recommendation marks the first allogeneic stem cell therapy to receive a positive CHMP opinion in Europe.
“Following today’s news, physicians and surgeons in Europe can look forward to offering these Crohn’s disease patients a novel and minimally invasive alternative treatment option in the future, which in clinical trials achieved higher combined remission and lower relapse rates* than the current standard of care,” said Professor Julian Panés, Head of the Gastroenterology Department at the Hospital Clinic of Barcelona (Spain) and President of the European Crohn's and Colitis Organisation (ECCO). “Perianal fistulas are estimated to affect up to 28% of patients in the first two decades after Crohn’s disease diagnosis and Cx601 offers new hope for those suffering from this severe and debilitating condition.”
Cx601 was assessed by the CAT, the EMA’s specialized scientific committee for Advanced Therapy Medicinal Products (ATMP), such as gene or cell therapies. The positive CHMP opinion was based on results from TiGenix’s Phase III ADMIRE-CD pivotal trial. The ADMIRE-CD trial is a randomized, double-blind, controlled, Phase III trial designed to investigate the efficacy and safety of investigational compound Cx601.3 24-week results were published in The Lancet and showed that Cx601 achieved statistically significant superiority versus the control group in the primary efficacy endpoint of combined remission.†,1 In addition, the rates and types of treatment related adverse events (non-serious and serious) and number of discontinuations due to adverse events were comparable between Cx601 and control arms, the most common of which were anal abscess and proctalgia.1 Further follow-up data indicated that Cx601 maintained long-term remission of treatment refractory complex perianal fistulas in patients with Crohn’s disease over 52 weeks.4
Dr. María Pascual, VP Regulatory Affairs and Corporate Quality at TiGenix, said, “We believe that this first approval recommendation for an allogeneic stem cell therapy in Europe reflects the maturity of our technology and its potential to offer new approaches for difficult to treat conditions. We have worked closely with the EMA and provided a robust data package from a well-designed clinical trial with challenging endpoints. In parallel, we will continue working hard to obtain regulatory approval in the U.S. and to develop Cx601 for additional indications, to fulfil our aim of allowing patients to benefit from the full potential of Cx601 across multiple geographies and diseases.”
The opinion will now be referred to the European Commission with a decision anticipated in the coming months. An MA will allow Cx601 to be marketed in all 28 member states of the EU, plus Norway, Iceland and Lichtenstein.
Cx601 has been licensed to Takeda for the exclusive development and commercialization outside of the U.S. Receipt of the MA will trigger a milestone payment from Takeda to TiGenix of €15 million. The companies have been working closely together to advance preparations for commercialization, with a potential start of the commercial launch by Takeda anticipated after MA is transferred from TiGenix to Takeda.
“Today’s positive CHMP opinion is a crucial step to bringing a new treatment option to patients with complex perianal fistulas in Crohn’s disease,” said Dr. Asit Parikh, Head of Takeda’s Gastroenterology Therapeutic Area Unit. “We would like to thank the scientific community and patients involved in the ADMIRE-CD trial for their support in helping us reach this important milestone. We remain committed to delivering innovative, therapeutic options for patients suffering from gastrointestinal disorders.”
Complex perianal fistulas are considered one of the most disabling complications of Crohn’s disease5 and can cause intense pain6 and swelling, infection and incontinence.1 Despite available therapies and surgical advancements, they currently remain challenging for clinicians to treat7 and have a significant negative impact on patient quality of life.

Please Log in or Create an account to join the conversation.

Board moderator and Site-owner. I still regret the day I started analysing the prospects of MacroPore (now Cytori) back in 2004- a left-over from the tech-bubble at that time from the century change in my portfolio- and became addicted to Cytori´s fat cell technology. :cry:
  • Page:
  • 1
Time to create page: 0.072 seconds

Copyright Information

Copyright Fas Kuiters © 2016 young-foxes.com. All Rights Reserved.
This page is made with Joomla CMS and its various templates designed by Fas Kuiters with the excellent Themler tool.



Shared Spreadsheet Links

DOV´s Revised Projections for the Periods 2017 until 2020

Shareble link : HERE

Fas Kuiters Websites